The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The IPSS-del(5q): a newly developed prognostic score for MDS with isolated 5q deletion
In this video, Maria Julia Montoro, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, briefly discusses the development of a new prognostic score, the IPSS-del(5q), for myelodysplastic syndrome (MDS) with isolated 5q deletion. Around 25% of patients with MDS-del5q progress to acute myeloid leukemia (AML), and this six-variable risk score aims to identify these patients, offering a valuable tool for clinicians. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have the biggest cohort of MDS-del5q patients, which are typically characteristic because it presents a really good prognosis. So we decided to analyze… but they have very good prognosis, but around 25% of them finally progressed to acute myeloid leukemia. So we wondered why these patients progressed to acute myeloid leukemia, and the objective of the study was to try to find or to define which characteristics impact on the prognosis of these patients...
We have the biggest cohort of MDS-del5q patients, which are typically characteristic because it presents a really good prognosis. So we decided to analyze… but they have very good prognosis, but around 25% of them finally progressed to acute myeloid leukemia. So we wondered why these patients progressed to acute myeloid leukemia, and the objective of the study was to try to find or to define which characteristics impact on the prognosis of these patients. We found some clinical and biological variables that impacted on the prognosis and finally we say to create a specific risk score for these patients and with six really simple variables we found the score that best defines the prognosis of these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
